Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 3, 2012, Pages 496-505

  Vavricka, Stephan R ^a   Spigaglia, Sabrina M ^a   Rogler, Gerhard ^a   Pittet, Valérie ^b   Michetti, Pierre ^c   Felley, Christian ^c   Mottet, Christian ^c   Braegger, Christian P ^a   Rogler, Daniela ^a   Straumann, Alex ^d   Bauerfeind, Peter ^a   Fried, Michael ^a   Schoepfer, Alain M ^c,e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

diagnosis; diagnostic delay; IBD; risk factors

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; COLITIS; CONSULTATION; CONTROLLED STUDY; CROHN DISEASE; DELAYED DIAGNOSIS; FEMALE; GENDER; HUMAN; ILEUM DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; SWITZERLAND; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CONFIDENCE INTERVALS; CROHN DISEASE; DELAYED DIAGNOSIS; FEMALE; HUMANS; ILEAL DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; RISK FACTORS; SWITZERLAND; TIME FACTORS; YOUNG ADULT;

EID: 84857369326     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21719     Document Type: Article

References (27)

1. Bercik P, Verdu EF, Collins SM,. Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am. 2005; 34: 235-245. (Pubitemid 40615953)
2. Talley NJ, Phillips SM, Melton LJ, et al. Diagnostic value of the Manning criteria in irritable bowel syndrome. Gut. 1990; 31: 77-81. (Pubitemid 20037984)
3. Hammer J, Talley NJ,. Value of different diagnostic criteria for the irritable bowel syndrome among men and women. J Clin Gastroenterol. 2008; 42: 160-166.
4. Dotan I,. Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification. Expert Rev Gastroenterol Hepatol. 2007; 1: 265-274.
5. Perminow G, Brackmann S, Lyckander LG, et al. A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005-07, showing increased incidence in Crohn's disease. Scand J Gastroenterol. 2009; 44: 446-456.
6. Perminow G, Frigessi A, Rydning A, et al. Incidence and clinical presentation of IBD in children: comparison between prospective and retrospective data in a selected Norwegian population. Scand J Gastroenterol. 2006; 41: 1433-1439. (Pubitemid 44764404)
7. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007; 13: 254-261. (Pubitemid 46465905)
8. Pimentel M, Chang M, Chow WJ, et al. Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol. 2000; 95: 3458-3462.
9. Markowitz J,. Early inflammatory bowel disease: different treatment response to specific or all medications? Dig Dis. 2009; 27: 358-365.
10. Etchevers MJ, Aceituno M, Sans M,. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 5512-5518.
11. Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn's disease. Inflamm Bowel Dis. 2008; 14: 949-954.
12. Gupta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early compared to later-onset pediatric Crohn's disease. Am J Gastroenterol. 2008; 103: 2092-2098.
13. Ricart E, Garcia-Bosch O, Ordas I, et al. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol. 2008; 14: 5523-5527.
14. Corrao G, Tragnone A, Caprilli R, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception, and breastfeeding in Italy: a nationwide case-control study. Intern J Epidemiol. 1998; 27: 397-404. (Pubitemid 28336965)
15. Rubin DT, Hanauer SB,. Smoking and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000; 12: 855-862. (Pubitemid 30663897)
16. Katschinski B, Fingerle D, Scherbaum B, et al. Oral contraceptive use and cigarette smoking in Crohn's disease. Dig Dis Sci. 1993; 38: 1596-1600. (Pubitemid 23271412)
17. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol. 2009; 38: 922-931.
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
19. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-1845. (Pubitemid 24188135)
20. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (Suppl1): i1-15. (Pubitemid 43268290)
21. Mekhjian HS, Switz DM, Melnyk CS, et al. Clinical features and natural history of Crohn's disease. Gastroenterology. 1979; 77: 898-906. (Pubitemid 9257853)
22. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-1385. (Pubitemid 39062279)
23. Gollop JH, Phillips SF, Melton LJ 3rd, et al. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut. 1998; 29: 49-56.
24. Loftus EV Jr, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology. 1998; 114: 1161-1168 (erratum: Gastroenterology. 1999; 116: 1507). (Pubitemid 28243901)
25. Simrén M, Axelsson J, Gillberg R, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002; 97: 389-396. (Pubitemid 34160766)
26. Singh S, Graff LA, Bernstein CN,. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol. 2009; 104: 1298-1313.
27. Wilcox GM, Mattia AR,. Rofecoxib and inflammatory bowel disease: clinical and pathologic observations. J Clin Gastroenterol. 2005; 39: 142-143. (Pubitemid 40130028)